Ergoteles LLC Amicus Therapeutics, Inc. Transaction History

Ergoteles LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$10.72 - $13.3 $2.8 Million - $3.48 Million	-261,595 Reduced 81.2%	60,549 $760,000
Q1 2023 May 10, 2023	BUY	$10.91 - $13.54 $1.23 Million - $1.53 Million	112,678 Added 53.79%	322,144 $3.57 Million
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $1.81 Million - $2.33 Million	183,197 Added 697.39%	209,466 $2.56 Million
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $257,961 - $334,929	26,269 New	26,269 $274,000
Q3 2021 Nov 15, 2021	SELL	$8.74 - $11.84 $154,156 - $208,833	-17,638 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$8.71 - $10.72 $153,626 - $189,079	17,638 New	17,638 $170,000
Q4 2020 Feb 11, 2021	SELL	$13.47 - $24.89 $243,807 - $450,509	-18,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$12.89 - $15.89 $233,309 - $287,609	18,100 New	18,100 $256,000

312

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.64B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.